| ￥3000 | |
| Z05351-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||
| Protein Construction |
|
||||
| Purity |
>?95%?as?determined?by?Bis?Tris?PAGE? >?95%?as?determined?by?HPLC |
||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 28.8 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 45-60 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
The purity of GHR/Growth Hormone R, His, Human is greater than 95% as determined by SEC-HPLC. ?
GHR/Growth Hormone R, His, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95% ?
| Target Background | Pegvisomant, a growth hormone receptor (GHR) antagonist, is a well-known drug that was designed to treat acromegaly. However, recent studies have indicated that the GHR is a 'moonlighting' protein that may exhibit dual functions based on its localization in the plasma membrane and nucleus. |
| Synonyms | GH receptor; GHBP; GHR; GHR/BP |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
